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Background: PDE3A is part of a SERCA2 signaling complex in cardiac myocytes.
Results: PDE3, not PDE4, regulates the activation of SERCA2 by PKA in human myocardium; phosphorylation of PDE3A1 at
Ser-292/Ser-293 promotes its integration into the SERCA2 signaling complex.
Conclusion: PDE3A1 regulates cAMP-mediated control of SERCA2 through its phosphorylation-dependent interaction with
SERCA2.
Significance: Targeted disruption of the PDE3A1-SERCA2 interaction may provide a new therapeutic approach for heart
failure.
Cyclic nucleotide phosphodiesterase 3A (PDE3) regulates
cAMP-mediated signaling in the heart, and PDE3 inhibitors
augment contractility in patients with heart failure. Studies in
mice showed that PDE3A, not PDE3B, is the subfamily respon-
sible for these inotropic effects and that murine PDE3A1 asso-
ciates with sarcoplasmic reticulum Ca2 ATPase 2 (SERCA2),
phospholamban (PLB), and AKAP18 in a multiprotein signalo-
some in human sarcoplasmic reticulum (SR). Immunohisto-
chemical staining demonstrated that PDE3A co-localizes in
Z-bands of human cardiac myocytes with desmin, SERCA2,
PLB, andAKAP18. In humanSR fractions, cAMP increasedPLB
phosphorylation and SERCA2 activity; this was potentiated by
PDE3 inhibition but not by PDE4 inhibition. During gel filtra-
tion chromatography of solubilized SRmembranes, PDE3 activ-
ity was recovered in distinct highmolecular weight (HMW) and
low molecular weight (LMW) peaks. HMW peaks contained
PDE3A1 and PDE3A2, whereas LMW peaks contained
PDE3A1, PDE3A2, and PDE3A3.Western blotting showed that
endogenous HMW PDE3A1 was the principal PKA-phosphor-
ylated isoform. Phosphorylation of endogenous PDE3A by
rPKAc increased cAMP-hydrolytic activity, correlated with
shift of PDE3A from LMW to HMW peaks, and increased co-
immunoprecipitation of SERCA2, cav3, PKA regulatory subunit
(PKARII), PP2A, and AKAP18 with PDE3A. In experiments
with recombinant proteins, phosphorylation of recombinant
human PDE3A isoforms by recombinant PKA catalytic subunit
increased co-immunoprecipitation with rSERCA2 and rat
rAKAP18 (recombinant AKAP18). Deletion of the recombinant
humanPDE3A1/PDE3A2N terminus blocked interactionswith
recombinant SERCA2. Serine-to-alanine substitutions identi-
fied Ser-292/Ser-293, a site unique to human PDE3A1, as the
principal site regulating its interaction with SERCA2. These
results indicate that phosphorylation of human PDE3A1 at a
PKA site in its unique N-terminal extension promotes its incor-
poration into SERCA2/AKAP18 signalosomes, where it
regulates a discrete cAMP pool that controls contractility by
modulating phosphorylation-dependent protein-protein inter-
actions, PLB phosphorylation, and SERCA2 activity.
Enzymes in the cyclic nucleotide phosphodiesterase 3
(PDE3)2 family of cyclic nucleotide phosphodiesterases have
an important role in regulating cAMP-mediated signaling in
cardiac myocytes. Inhibitors of these enzymes are used to
increase the force of contraction in patients with heart failure.
The observation that inotropic responses to PDE3 inhibition
are preserved in PDE3B-KO mice but not in PDE3A-KO mice
indicates that PDE3A isoforms are specifically involved in the
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regulation of contractility (1, 2). Furthermore, in mouse myo-
cardium, the PDE3A1 isoform was found to be a component of
a SERCA2-PLB-AKAP18 multiprotein complex or “signalo-
some” that regulates the transport of cytoplasmic Ca2 into the
sarcoplasmic reticulum (2–3). By potentiating cAMP-depen-
dent phosphorylation of phospholamban in this signalosome,
PDE3 inhibition stimulates Ca2 uptake and increases the
amplitude of intracellular Ca2 cycling. In renal collecting duct
principal cells, incorporation of PDE4D into a signalosome
containing AKAP18 and aquaporin-2 (AQP2) plays an impor-
tant role in cAMP/PKA-mediated insertion of the AQP2 water
channel into the cell membrane and regulation of vasopressin-
induced water reabsorption (4).
Many of the interactions of PDE3 isoforms with other pro-
teins have been shown to be dependent upon their phosphory-
lation. This has been well established in the case of PDE3B
(5–12). Some of the protein-protein interactions of PDE3A iso-
forms have also been shown to be phosphorylation-dependent,
including those with 14-3-3 (13–15). More recently, it has
become clear that different isoforms of PDE3A, whose amino
acid sequences are identical except for varying lengths ofN-ter-
minal sequence, differ significantly with respect to these inter-
actions (15). PDE3A1 is found exclusively in intracellularmem-
branes of cardiacmyocytes and is preferentially phosphorylated
at the 14-3-3-binding site Ser-312 in response to PKA activa-
tion, whereas PDE3A2, which lacks the N-terminal 154 amino
acid sequence of PDE3A1, is preferentially phosphorylated at
the alternative 14-3-3-binding site Ser-428 in response to PKC
activation (15). PKA activation and PKC activation were found
to promote the association of PDE3A1 and PDE3A2 with dis-
tinct protein interactomes (15).
In the experiments described below, we identified compo-
nents of the SERCA2-PLB-AKAP18 signalosome in human
myocardium. We showed that PDE3, and not PDE4 (that has
also been shown to interact with PLB in human cardiac myo-
cytes (16)), regulates the phosphorylation of PLB and the stim-
ulation of SERCA2 activity and Ca2 transport by cAMP in
human SR fractions. The integration of PDE3A1 into the
SERCA2-regulatory signalosome involves direct interactions
with both AKAP18 and SERCA2 and is phosphorylation-de-
pendent. Interaction of PDE3A1 with SERCA2 is dependent
upon the phosphorylation of Ser-292/Ser-293, a multikinase
site within the unique N-terminal extension of PDE3A1.
MATERIALS ANDMETHODS
Use of humanheart samples in these studieswas approved by
review committees at NHLBI, NIH, and the University of Utah.
Materials
[-32P]ATP (3000 Ci/mmol) was obtained from MP Bio-
medicals (Solon, OH); rPKAc (catalog #14-440) and rSERCA2
(catalog #H00000488-P01) were obtained from Calbiochem
and Abnova, respectively. Anti-PLB (ab2865), -p-PLB
(ab15000), -AKAP-LBC (ab56917), and -AKAP18 (ab30987)
antibodies were from Abcam (Cambridge, MA). Antibodies to
PP2A (610556), PKA regulatory subunit (PKARII; 610626), and
PKAc (610981) were from BD Biosciences. Anti-PP1 antibody
(sc7482) and anti-caveolin-3 antibody (sc5310) were from
Santa Cruz Biotechnology; anti-SERCA2 antibody (MA3-910)
was from Affinity Bioreagents. Anti-phospho-PKA substrate
antibody (9621) was from Cell Signaling; anti-desmin antibody
(M0760) was from Dako. Protein G magnetic beads (88848)
were fromThermo Fisher Scientific (Rockford, IL);mouse anti-
FLAG M2 magnetic beads (M8823) and mouse anti-FLAG
M2-peroxidase HRP antibody (A8592) were from Sigma;
mouse anti-His mAbmagnetic beads (L00275) were fromGen-
script. Anti-myomesin antibody (mMac myomesin B4) was
obtained from Developmental Studies Hybridoma Bank (Uni-
versity of Iowa). Rabbit polyclonal antibody to human PDE3A
(accession number AAA35912) was generated against peptide
corresponding to amino acids 1127–1141 (GKPRGEEIPTQK-
PDQ) CT domain (C-terminal domain) and was affinity-puri-
fied as described below. For immunohistochemical studies, the
secondary antibodies, Alexa Fluor 488 or Alexa Fluor 594, were
from Molecular Probes. For SDS-PAGE and Western blots,
HRP-labeled secondary antibody and SuperSignal Westpico
andWestfemto chemiluminescent reagents were fromThermo
Fisher Scientific. Signals were detected with Image reader
LAS3000 (GE Healthcare). Other materials were obtained as
indicated.
Methods
Affinity Purification of Anti-human PDE3A-CT Antibody—
Approximately 30 mg of PDE3A-CT peptide (GKPRGEEIPT-
QKPDQ) was coupled to 3 ml of Affi-Gel 10 (Bio-Rad) beads
that were used to purify anti-PDE3A-CT rabbit polyclonal anti-
body. Immunized serumwas diluted (10 times)with 10mMTris
buffer, pH 7.5. Affi-Gel 10-PDE3A-CT-peptide beads and the
diluted serumwere rotated end-over-end for 16 h at 4 °C. After
centrifugation, the immunobeads were washed (3 times, 20 bed
volumes) with 10 mM Tris, pH 7.5. Anti-PDE3A antibody was
eluted from the beads by adding 5 ml of elution buffer (100 mM
glycine buffer, pH 2.5) and by rotating the mixture for 3 min.
The eluted antibodywas neutralized immediately with 1 MTris,
pH 7.5, and dialyzed at 4 °C against 1 liter of PBS overnight.
Dialyzed antibodywas reconstitutedwith 50%glycerol and kept
at 80 °C. Affinity-purified anti-PDE3A-CT antibodies were
used for all studies in this report.
Immunohistochemistry—Frozen heart blocks were prepared
from snap-frozen normal human heart samples obtained from
Capital Biosciences, Inc, and sections were made at a thickness
of 10 m using a microtome at 25 °C. Paraformaldehyde-
fixed cryostat heart sections were washed in PBS (3  5 min)
and blocked and permeabilized (6 h, 4 °C) in blocking buffer
(PBS containing 10% donkey serum and 0.05% Triton X-100).
Slides were incubated in blocking buffer with primary antibody
overnight and washed with PBS (3 5 min) before incubating
in blocking buffer for 2 h with the secondary antibodies, Alexa
Fluor 488 or Alexa Fluor 594. Anti-PDE3A-CT antibody, gen-
erated against human PDE3A aa 1127–1141 (GKPRGEEIPT-
QKPDQ), was used in these studies. As controls, slides were
incubated with nonimmune IgG or with primary anti-
PDE3A-CT antibodies incubated with blocking (immunizing)
peptide before staining with secondary antibody. For peptide
blocking/competition experiments,20g of anti-PDE3A-CT
antibody was combined with 100 g of blocking peptide in a
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small volume (500 l) of PBS and incubated (2 h at room tem-
perature or overnight at 4 °C). After blocking with the immu-
nizing peptides, antibody/peptide mixtures were diluted
into blocking buffer and used for staining of samples. Slides
were viewed with a Zeiss LSM510 laser scanning confocal
microscope.
Preparation of Subcellular Fractions of Human Myo-
cardium—Human myocardium was obtained from the left
ventricular free wall of explanted hearts from patients with idi-
opathic dilated cardiomyopathy undergoing cardiac transplan-
tation (University of Utah). Normal human heart samples were
also obtained from Capital Biosciences, Inc. (Rockville, MD).
Heart tissues were quickly washed in ice-cold PBS, chopped
with scissors, and homogenized (4 ml/g of tissue) at 4 °C in
buffer A (0.29 M sucrose, 10 mM MOPS, 2 mM EGTA, Roche
Applied Science protease inhibitor mixture, pH 7.0) with a
rotor-stator homogenizer (Omni International, Marietta, GA)
at 30,000 rpm (60–80 s on ice) followed by homogenization (on
ice, 20 strokes in a glass Dounce homogenizer). Homogenates
were centrifuged (11,000  g, 15 min) in a Beckman JA-20
rotor. Supernatants were further centrifuged (150,000 g, 1 h)
in a Beckman 55.2 Ti rotor, yielding cytosolic fractions and
pellets. Pellets were resuspended by hand homogenization
(glass-glass) in two volumes (relative to starting material) of
buffer Awithout EGTA.After recentrifugation (150,000 g for
1 h), pellets, i.e. “myocardial membrane fractions,” were sus-
pended in buffer A (without EGTA) using a Dounce homoge-
nizer and stored at 80 °C. Each preparation was made from
combined tissues from at least three different explanted hearts.
For some experiments myocardial membrane fractions were
suspended in buffer B (50 mM HEPES, 50 mM sucrose, 1 mM
EDTA, 10 mM pyrophosphate, 5 mM NaF, 100 mM NaCl, 5 mM
MgCl2, 0.1 M okadaic acid, Roche Applied Science protease
inhibitor mixture, pH 7.5). Myocardial membranes were then
solubilized by homogenization (using a Dounce homogenizer,
20 strokes) and incubation/rotation of homogenates with Non-
idet P40 (v/v, 1% final) (ThermoFisher Scientific) for 1 h at 4 °C.
Solubilized membrane proteins (supernatants) were obtained
by centrifugation (24,000 rev/min (98,500  g)) for 30 min at
4 °C using a Beckman SW41 Ti rotor.
For isolation of SR vesicles, 11,000  g supernatants were
centrifuged (45 min, 43,666 g) in a Beckman SW41 Ti rotor,
as described (17). The resultant pellets were resuspended in
buffer containing 0.6 M KCl and 20 mM Tris, pH 6.8, and cen-
trifuged (45min, 43,666 g). The final washed pellets contain-
ing SR fractions were suspended in buffer A and stored at
80 °C.
cAMP PDE Assay—PDE3 activity (that portion of total PDE
activity inhibited by 1.0M cilostamide, a selective PDE3 inhib-
itor), was measured by modification of our published method
(18) using 0.1 M [3H]cAMP (35000 cpm) as substrate. PDE
activity is expressed as pmol of cAMP hydrolyzed/min/mg.
Immunoprecipitation and Immunoblotting—In experiments
with solubilized myocardial membrane fractions and Superose
6 column fractions (Figs. 3 and 5), fractions were cleared by
incubation for 1 h at 4 °C with 5 g of rabbit non-immune IgG
and then with 50 l of Protein G magnetic beads for 30 min
before placing the tubes into a magnetic stand to collect the
beads against the side of the tube. Cleared fractions were trans-
ferred to new tubes and incubated overnight at 4 °C with spec-
ified antibodies or with non-immune IgG followed by incuba-
tion with fresh Protein Gmagnetic beads for 1 h before placing
the tubes into a magnetic stand to collect the beads. In experi-
ments with recombinant proteins (Figs. 6 and 7), fractions
(reaction mixtures) containing FLAG-tagged human PDE3A
variants (Fig. 6) orHis-taggedAKAP18 (Fig. 7) were cleared as
described above but incubated with 5 g of mouse non-im-
mune IgG and thenwith 50l ProteinGMagnetic beads before
placing the tubes in amagnetic stand to separate the beads from
the cleared fractions for immunoprecipitation. The cleared
fractions were transferred to new tubes and incubated with
mouse anti-FLAGM2 magnetic beads or mouse anti-His mAb
magnetic beads before placing the tubes into a magnetic stand
to collect the beads.
Immunoprecipitated proteins bound to the three types of
magnetic beads were washed (3, buffer B) and then eluted by
boiling (5 min) the beads in 200 l of Laemmli SDS sample
buffer (65 mMTris, pH 6.8, 2.5% SDS, 10% glycerol, and 0.002%
bromphenol bluewith 100mM-mercaptoethanol and 100mM
DTT). After boiling, magnetic beads were separated from the
eluted proteins by placing the tubes in a magnetic stand. Sam-
ples (15–20l) of eluted proteinswere subjected to SDS-PAGE,
electrotransferred to nitrocellulose membranes (Invitrogen),
and immunoblotted sequentially with appropriate primary
antibodies and HRP-labeled secondary antibodies or anti-
FLAGM2-HRP antibody. Immunoreactive proteins were
reacted with SupersignalWestpico or Westfemto chemilu-
minescent reagents; signals were detected with Image reader
LAS3000.
cAMP-dependent Phosphorylation of Endogenous PLB—
Resuspended human SR fractions (20g of protein) were phos-
phorylated in buffer containing 50mMHEPES, 5mMMgCl2, 50
mM sucrose, 100mMNaCl, 5 mMNaF, 10 mM PPi, 1 mM EDTA,
pH 7.6. After incubation (2 min, 30 °C) in the absence or pres-
ence of cilostamide (1 M) or rolipram (10 M), 0.5 mM ATP
and 0.1M cAMPwere added as indicated, and incubations (50
l final volume) were continued for 30 min. Reactions were
terminated by the addition of Laemmli SDS sample buffer (25
l). Samples were immediately boiled (5 min) and subjected to
SDS-PAGE. Phosphorylation of PLB Ser-16, and endogenous
PLB, PKAc, and PDE3A proteins were identified by Western
immunoblotting (Fig. 2A).
Effect of cAMP and Recombinant PKA Catalytic Subunit
(rPKAc) on 45Ca2 Uptake or SERCA Activity in Human SR
Vesicles—For experiments in Fig. 2, D–F, SR vesicle fractions
(50100 g), prepared as described above, were incubated (30
min, 30 °C) without or with the indicated concentrations of
cAMP, 250 units of rPKAc, or 1.0 M cilostamide (PDE3 inhib-
itor) in buffer containing 10 mM imidazole-HCl, pH 7.0, 0.1 M
okadaic acid, 10 mM MgCl2, 5 mM DTT, 0.5 mM ATP, and 1
phosphatase inhibitor mixture (1 rPKAc activity unit is defined
as the amount of enzyme required to transfer 1 nmol of phos-
phate to PKA peptide (GRTGRRNSI)/min at 30 °C). Reaction
mixtures were centrifuged (100,000 g, 30 min, 4 °C), and the
resulting pellets were resuspended in 0.3 M sucrose, 10 mM
K-PIPES buffer containing 1 phosphatase inhibitor mixture,
PDE3A Regulates SERCA2 Signaling in HumanMyocardium
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pH 7.0, for Ca2 uptake and SERCA activity assays as described
below.
Measurement of 45Ca2Uptake into SR Vesicles—For exper-
iments in Fig. 2, D–F, oxalate-dependent Ca2 uptake was
quantified as described previously (19). As described above,
after incubation (30 min, 30 °C) without or with various addi-
tions, SR vesicles were collected and resuspended in a sucrose/
K-PIPES buffer. Then portions (50 l, 10 g of protein) were
incubated at 37 °C for 1 min in 0.4 ml of Ca2 uptake buffer
consisting of 50 mM imidazole-HCl, pH 7.0, 100 mM KCl, 6 mM
MgCl2, 10mMNaN3 (to inhibitmitochondrial Ca2 uptake), 10
mM potassium oxalate, 20 M ruthenium red (to inhibit SR
Ca2 release), 0.1 mM EGTA, 45CaCl2 (10,000 dpm/nmol)
(PerkinElmer Life Sciences, catalog #NEZ013), and unlabeled
CaCl2 (0.5M freeCa2). Uptakewas initiated by adding 50mM
ATP (50 l), and reactions were terminated by filtration
through 0.45-m Millipore filters. After washing four times
with 4 ml of buffer containing 140 mM KCl, 10 mM NaCl, 2 mM
MgCl2, 1 mM CaCl2, and 50 mM imidazole-HCl, pH 7.0, radio-
activity retained on the filters was quantified by liquid scintilla-
tion counting. Free Ca2 was calculated using a MAXCHELATOR
program obtained at Stanford University.
SERCA Activity Assay—In Fig. 2F, Ca2-ATPase activity in
SR fractions was determined by measuring the amount of Pi
released after the addition of ATP using the malachite green
ATPase method (20). Briefly, as described above, after incuba-
tion (30 min, 30 °C) without or with 250 units of rPKAc, SR
vesicles were isolated and suspended in sucrose/K-PIPES
buffer. Then samples (50 l, 10 g of protein) were assayed for
SERCA2 enzymatic activity in the presence or absence of thap-
sigargin (10 M), as SERCA2 activity was determined as that
portion of total activity inhibited by thapsigargin. The assay
mixture (total volume, 125 l) contained 0.125 M KCl, 20 mM
imidazole, pH7.0, 0.1mMEGTA, 0.103mMCaCl2, 5mMMgCl2,
1M ionomycin, and 10g of SR. To initiate the reaction, 25l
of substrate (1.25 mM ATP) was added to a final concentration
of 0.25 mM. The mixture was incubated at room temperature
for 3 min. The reaction was terminated by adding 25 l of 250
g/liter TCA, vortexed quickly, and centrifuged (8000  g, 3
min). Supernatants (20 l) were added to 96-well plates fol-
lowed by color reagent (100 l/sample), which consisted of 54
mM ammoniummolybdate and 0.73mMmalachite green. After
1 min sodium citrate (340 g/liter, 10 l) was added with gentle
shaking (room temperature for 20 min), after which plates
were scanned at 650 nm. Pi was calculated by converting
OD650 to nanomoles by means of a standard curve.
Gel FiltrationChromatography on Superose 6 Columns—Sol-
ubilized myocardial membranes (1.0 ml, 3 mg of total protein),
prepared as described above, were applied to a Superose 6 HR
10/30 column (ÄKTA FPLC System, GE Healthcare) that was
equilibrated and eluted with buffer C (buffer B without sucrose
containing 150mMNaCl and 1%Nonidet P-40) (Fig. 3A). Cyto-
solic fractions (1.0 ml, 3 mg of total protein), prepared as
described above, were also applied to Superose 6 that was equil-
ibrated and eluted with buffer D (buffer C, without Nonidet
P-40) (Fig. 3B). Portions of the fractions (0.5 ml) were used for
assay of PDE3 activity or SDS-PAGE/Western blotting (using
anti-PDE3A-CT antibodies) (Fig. 3, A and B) as described
above. In some experiments (Fig. 3C), portions of eluted HMW
(H) and LMW (L) peaks from solubilized membrane fractions
(M) and cytosol fractions (C) were pooled and concentrated. As
described above (see “Immunoprecipitation and Immunoblot-
ting”), fractions were cleared by incubation with 5 g of rabbit
non-immune IgG and then with 50 l of Protein G magnetic
beads for 30min before placing the tubes into amagnetic stand
to collect the beads against the side of the tube. As presented in
Fig. 3C, cleared fractions were transferred to new tubes and
incubated overnight at 4 °C with 10 g of non-immune IgG
(IgG lane) or with 10 g of anti-PDE3A-CT (PDE3A lanes)
followed by incubation (1 h, 4 °C) and immunoprecipitation
with 50l of fresh Protein Gmagnetic beads before placing the
tubes into a magnetic stand to collect the beads. Immunopre-
cipitated proteins bound to the magnetic beads were washed
(3, buffer B) and then eluted by boiling (5 min) in 200 l of
Laemmli SDS sample buffer. After boiling,magnetic beadswere
separated from the eluted proteins by placing the tubes in a
magnetic stand. Samples of eluted proteins were subjected to
SDS-PAGE and immunoblotting with anti-pPKA substrate or
anti-PDE3A-CT (PDE3A) antibodies (Fig. 3C) as described
above.
In Vitro Phosphorylation of Endogenous PDE3A—For exper-
iments in Fig. 3D, solubilized membrane fractions (500 g)
were cleared with 5 g of rabbit non-immune IgG and 50 l of
Protein G magnetic beads, and PDE3A was immunoprecipi-
tated using 10 g of anti-PDE3A-CT and 50 l of Protein G
magnetic beads as described above. Immunoprecipitated
PDE3A bound to the magnetic beads was incubated for 1 h at
30 °C in phosphorylation buffer (50 mM HEPES, pH 7.5, 5 mM
MgCl2, 100 mM NaCl, 1 mM EDTA, 10 mM PPi, 5 mM NaF, 0.1
M okadaic acid) with 200 M ATP or 200 M ATP supple-
mented with [-32P]ATP (10 Ci per reaction; 3000 Ci/mmol
stock) in the absence or presence of 250 units of rPKAc or
rPKAc plus 10 M PKAc inhibitor (PKI) . After the incubation,
tubes were placed in a magnetic stand to separate the beads
from the reaction mixtures, and beads (with bound immuno-
precipitated PDE3A) were washed (3, buffer B).
As indicated in Fig. 3D (lower panel) immunoprecipitated
PDE3A (not incubated with [-32P]ATP) was assayed for PDE3
activity using [3H]cAMP as substrate. The assays were termi-
nated, and tubeswere placed in amagnetic stand to separate the
beads from the reaction mixtures. In the separated reaction
mixtures, the product 5-[3H]AMP was converted to [3H]ade-
nosine, which was quantified as described in our published
method (18).
As shown in Fig. 3D (upper panel), after incubation of immu-
noprecipitated PDE3A with rPKAc and [-32P]ATP, the beads
were separated from the reaction mixtures and washed as
described above. 32P-Labeled PDE3A bound to the magnetic
beads was eluted by boiling the beads (5 min) in Laemmli SDS
sample buffer and then by placing the tubes in amagnetic stand
to separate the eluted 32P-labeled PDE3A from the magnetic
beads. Samples of eluted 32P-labeled PDE3A were subjected to
SDS-PAGE. -32P phosphorylation of PDE3A was detected by
scanning the wet gels by phosphorimaging (GE Healthcare).
Proteins on wet gels were then electrophoretically transferred
to nitrocellulose membranes, and PDE3A was identified by
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Western blotting using anti-PDE3A antibody (Fig. 3D, middle
panel). PKI blocked rPKAc-induced phosphorylation and acti-
vation of PDE3A.
In other experiments (Fig. 4) chromatography of solubilized
myocardial membranes (3 mg) on Superose 6 was repeated 2
times and LMW fractions (#24–34, Fig. 3A) were pooled and
concentrated via Centriprep YM-3 (centrifugal filter units with
Ultracel-3 membranes (nominal molecular weight limit, 3
kDa)). The concentrated fractions were split, and after incuba-
tion for 1 h at 30 °C without (LMW control) or with (LMW 
PKA) rPKAc in phosphorylation buffer containing 200MATP
and 5 mM MgCl2 were re-chromatographed on Superose 6
(Fig. 4). Portions of the fractions (0.5 ml) were used for assay of
PDE3 activity or SDS-PAGE/Western blotting (using anti-
PDE3A-CT and other indicated antibodies) as described above.
Co-immunoprecipitation of PDE3A with Components of
SERCA2 Regulatory Signalosomes from Pooled LMW Fractions
after Incubation with or without rPKAc—For these studies (Fig.
5), pooled LMWSuperose 6 fractions from solubilizedmyocar-
dial membranes (two experiments) were prepared as described
above (cf. Figs. 3A and 4). These LMW fractions were concen-
trated and split into three fractions that were then incubated (1
h, 30 °C) in phosphorylation buffer containing 200MATP and
5 mM MgCl2, without (IgG, Control) or with (PKA-C) rPKAc.
To study co-immunoprecipitation of PDE3Awith components
of the SERCA2/AKAP18 signalosome (Fig. 5), at the comple-
tion of these reactions the three LMW fractions were cleared
with rabbit non-immune IgG (5 g)and Protein G magnetic
beads (50l) as described above and then incubated (overnight,
4 °C) with non-immune IgG (10 g) (IgG) or anti-PDE3A-CT
antibody (10g) (control, PKA-C) before incubation (1 h, 4 °C)
with Protein G magnetic beads. Tubes were placed in a mag-
netic stand to separate the beads from the reaction mixtures.
Immunoprecipitated proteins bound to Protein G magnetic
beads were washed and eluted as described above, and portions
of eluted samples were subjected to SDS-PAGE, transferred to
nitrocellulose membranes, and immunoblotted with indicated
antibodies (Fig. 5). Total membrane proteins (10 g, input)
were loaded on gels as controls.
Co-immunoprecipitation of FLAG-tagged Recombinant
Human PDE3A (rhPDE3A) Variants and rSERCA2 after Incu-
bation with or without rPKAc—FLAG-tagged rhPDE3A1 (open
reading frame, accession number NP_000912) and its phos-
phorylation site mutants (rhPDE3A1-S292A/S293A (P1),
rhPDE3A1-S312A (P2), rhPDE3A1-S428A (P3), rhPDE3A1-
S438A (P4), and rhPDE3A1-S292A/S293A/S312A/S438A (P5)
(Fig. 6B) were synthesized by Genscript, Inc (Piscataway, NJ)
and subcloned into pAcSG2 baculoviral expression vector.
FLAG-tagged rhPDE3A variants and phosphorylation site
mutants were expressed in SF21 cells ((10–20)  106 SF21
cells/75-cm2 flask) as described (21, 22). SF21 cells were har-
vested, sedimented (10 min, 1000 g, 4 °C), washed twice with
ice-cold PBS, resuspended, homogenized (in a Dounce homog-
enizer) in buffer B, and sonicated on ice (2 20 s pulses, output
2, 40% cycle) with a Sonifier cell disruptor 350 (Branson Sonic
Power Co., Danbury, CT). After incubation/rotation in buffer B
containing 1% (v/v) Nonidet P40, the sonicated homogenates
were centrifuged (20 min, 4 °C, 12,000  g). The supernatants
containing rhPDE3A variants were used for experiments.
Purified human rSERCA2 (full-length ORF (accession num-
ber NP_001672.1, 1–997 aa)) protein with a GST tag at its N
terminus was purchased fromAbnova (Taiwan). rSERCA2 and
FLAG-tagged rhPDE3A variants (usually 50 arbitrary units, 1
unit being the amount of PDE3 that hydrolyzed 1 pmol of
cAMP/min at 30 °C) were incubated (30 min, 30 °C) in phos-
phorylation buffer containing 5 mM MgCl2, 200 M ATP with
or without 50 units of rPKAc (final volume, 200 l). Reactions
were stopped by the dilution of reactionmixtures to 1.0ml with
buffer B containing 1mg/ml SF21 cell supernatants and cleared
as described above (see “Immunoprecipitation and Immuno-
blotting”) by incubation with 5 g of mouse non-immune IgG
and then with 50 l of Protein G magnetic beads. To block
nonspecific binding of proteins to anti-FLAG M2 magnetic
beads,1 ml of anti-FLAGM2 magnetic beads was incubated
(overnight, 4° C) with 5 ml (1 mg/ml) of Sf21 cell supernatants
(prepared by homogenization of cells in buffer B containing 1%
Nonidet P-40 and centrifugation (12,000 g, 20 min)).
Treated anti-FLAG M2 magnetic beads were placed in a
magnetic stand to separate the beads from Sf21 cell superna-
tants and washed (PBS, 3). These washed magnetic beads
were used for immunoprecipitation of recombinant proteins
(25l, 2 h, 4 °C) from the cleared reactionmixtures. Tubeswere
placed in a magnetic stand to separate the beads from the reac-
tion mixtures, which were removed. Immunoprecipitated pro-
teins bound to the anti-FLAG-M2magnetic beadswerewashed
and eluted by boiling in Laemmli SDS sample buffer (200l). As
described above, tubes were placed in a magnetic stand to sep-
arate the beads from the eluted proteins, and samples of eluted
proteins as well as of SERCA2 (reaction mixture input protein)
were subjected to SDS-PAGE and Western immunoblotting
with the indicated antibodies as described above.
Co-immunoprecipitation of His-tagged Recombinant Rat
AKAP18 (rAKAP18) with FLAG-tagged rhPDE3A1 after
Incubation with or without rPKAc—His-tagged rAKAP18
open reading frame (accession number NP_001001801, (4))
was synthesized by Genscript, Inc. (Piscataway, NJ), subcloned
into pAcSG2 baculoviral expression vector, and expressed in
SF21 cells (21). A comparison of the translated sequences of
human AKAP18 (accession number NP_057461 and
AK300587; 348-aa residues) and rat AKAP18 (4) (accession
number Q6JP77; 353 aa residues) indicate that 8 of the first 12
aa residues of human AKAP18 and rat AKAP18 are identical
and that the proteins are homologous (74% aa identity). SF21
cell supernatants, containing His-tagged rAKAP18, were pre-
pared as described above. FLAG-tagged rhPDE3A1 (usually 50
arbitrary units) was incubated (30 min, 30 °C) with rAKAP18
(50 ng) in phosphorylation buffer containing 2 mM DTT, 5 mM
MgCl2, and 200 MATP (final volume, 300 l) with or without
different concentrations of rPKAc (Fig. 7B) andwith or without
50 units of rPKAc (Fig. 7C). As a control, in Fig. 7C, rhPDE3A1
(50 units) was incubated with or without rPKAc (50 units) and
with SF21 cell supernatants that contained or did not contain
rAKAP18. Reactions were stopped by dilution of reaction
mixtures to 1.0 ml with buffer B containing 1 mg/ml SF21 cell
supernatants and cleared by incubation with 5 g of mouse
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non-immune IgG and then with 50 l of Protein G magnetic
beads as described above. Anti-His mAb magnetic beads incu-
bated with SF21 cell supernatants as described above for anti-
FLAGM2 magnetic beads were used for immunoprecipitation
of recombinant proteins (25l, 2 h, 4 °C). Tubes were placed in
a magnetic stand to separate the beads from the reaction mix-
tures, which were removed. Immunoprecipitated proteins
bound to anti-HismAbmagnetic beadswerewashed and eluted
by boiling in Laemmli SDS sample buffer (200l). As described
above, samples of eluted immunoprecipitated proteins as well
as of reaction mixtures (“input proteins”) were subjected to
SDS-PAGE and immunoblotted with indicated antibodies.
RESULTS
PDE3A Co-localizes with PLB, SERCA2, and AKAP18 in the
Z-bands of HumanCardiacMyocytes—The intracellular distri-
bution of PDE3A in cryostat sections of normal human left
ventricle was examined by immunostaining with peptide affin-
ity-purified anti-PDE3A-CT antibodies (Fig. 1). Consistent
with our previous studies (2, 23), co-staining with anti-
PDE3A-CT and anti-desmin antibodies demonstrated that
PDE3A is distributed in a striated pattern in the Z-lines of
human cardiac myocytes (Fig. 1, A and B), with little co-local-
ization with myomesin (M-line marker protein) (Fig. 1B).
PDE3A co-localized with PLB, SERCA2, and an AKAP18 vari-
ant (detected by antibodies to human AKAP18 (Abcam: Ab
30987)) (Fig. 1, A and B).
PDE3 Inhibition Potentiates cAMP-dependent Phosphoryla-
tion of PLB and Its Stimulation of Ca2Uptake inHumanMyo-
cardial Membranes—The effects of PDE3 inhibition on PLB
phosphorylation and Ca2 uptake were examined in SR frac-
tions prepared fromhuman left ventricularmyocardium.At 0.1
M cAMP, phosphorylation of PLB at Ser-16 by endogenous
PKA was stimulated by the PDE3-selective inhibitor cilosta-
mide (Fig. 2, A and B). Because PDE4 has also been found to
co-immunoprecipitate with PLB in subcellular preparations
from human myocardium (16), we tested the effect of the
PDE4-specific inhibitor rolipram on PLB phosphorylation and
found no effect (Fig. 2, A and B). This result corresponds to the
lower amount of rolipram-sensitive cAMP hydrolytic activity
relative to cilostamide-sensitive cAMP hydrolytic activity in
these SR preparations (Fig. 2C). cAMP increased ATP-depen-
dent, oxalate-supported Ca2 uptake (Fig. 2D), and this effect
was potentiated by cilostamide (Fig. 2E). The addition of rPKAc
stimulated both Ca2 uptake and SERCA2 activity (Fig. 2F).
These results indicate that PDE3has a specific role in regulating
phosphorylation of PLB by cAMP/PKA and the consequent
stimulation of Ca2 uptake in human myocardium.
Gel Filtration Chromatography of PDE3A Isoforms from
Human Myocardium—In previous studies we showed that the
phosphorylation of rPDE3A isoforms in transfected HEK293
cells promotes their interactions with other proteins (15). To
address whether phosphorylation might promote the integra-
FIGURE1.PDE3A, SERCA2, PLB, andAKAP18 co-localize in theZ-bands innormal humanmyocardium.A, cryostat sections of normal human left ventricle
were prepared and, as described under “Methods,” permeabilized, blocked, and then incubated in blocking buffer with rabbit anti-PDE3A-CT, anti-desmin,
anti-SERCA2, anti-PLB, anti-AKAP18, and anti-myomesin primary antibodies followed by incubation with Alexa Fluor 488- or 594-conjugated anti-mouse or
anti-rabbit secondary antibodies. Signals were detected with a Zeiss LSM510 laser scanning confocal microscope. From the left: first column, red fluorescent
staining formarker proteins: desmin, SERCA2,myomesin, PLB, andAKAP18; second column, green fluorescence staining for PDE3A; third column, DAPI staining
of nuclei (blue); fourth column, merged images of PDE3A, marker proteins, and DAPI indicate that PDE3A exhibits a striated pattern and co-localizes with
desmin, SERCA2, PLB, andAKAP18. B, merged images from stacks of 10–15 sections (with 1-m intervals) reveal colocalization of PDE3Awith desmin, SERCA2,
PLB, andAKAP18but notwithmyomesin (labelingM-line Red). X-Y (center), aboveX-Z (top), andY-Z (right) planes are at the indicatedpositions. Representative
images from three independent experiments are shown.
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tion of PDE3A into multiprotein SERCA2 signalosomes in car-
diac myocytes, we analyzed cytosolic and Nonidet P-40-solubi-
lized membrane proteins from human left ventricular
myocardium by Superose 6 gel filtration chromatography (Fig.
3). As seen in Fig. 3A, PDE3 activity in solubilized myocardial
membrane proteins was recovered in distinct HMW (3000
kDa) and LMW (700 kDa) peaks.Western blotting with anti-
PDE3A antibodies indicated that the HMW and LMW peaks
contained all three PDE3A isoforms. In contrast, upon Super-
ose 6 chromatography of cytosolic fractions, from which
PDE3A1 is absent, PDE3A2 and PDE3A3 eluted in a single
LMWpeak (Fig. 3B). As seen in Fig. 3C, immunoprecipitation
of PDE3A from pooled HMW or LMW peaks of solubilized
membranes followed byWestern blotting with anti-phospho
PKA substrate and anti-PDE3A-CT antibodies demon-
strated that endogenous PDE3A1 in HMW peaks was the
most highly PKA-phosphorylated PDE3A isoform. These
results suggested that phosphorylation of endogenous
PDE3A1 by PKA may be involved in its incorporation into
HMW multiprotein complexes.
To confirm these findings, studies of the phosphorylation of
endogenous PDE3A by rPKAc in the absence or presence of
[-32P]ATP or unlabeled ATP were carried out in vitro using
immunoprecipitated PDE3A from solubilized myocardial
membranes. As seen in Fig. 3D (upper panels), after immuno-
precipitated PDE3A was incubated with [-32P]ATP in the
absence (Ctrl) or presence of rPKAc or rPKAc plus PKI peptide,
phosphorimaging of wet gels after SDS-PAGE combined with
Western blotting demonstrated that both PDE3A1 and
PDE3A2 could be markedly phosphorylated by rPKAc, with
little if any increase in the phosphorylation of PDE3A3. PKI
blocked phosphorylation of PDE3A1 and PDE3A2. As seen in
Fig. 3D (lower panel), phosphorylation of immunoprecipitated
PDE3A by rPKAc was accompanied by stimulation of PDE3A
hydrolytic activity (35% compared with controls, p 0.01). PKI
blocked rPKAc-induced activation of PDE3A.
FIGURE 2. cAMP, PKA, and PDE3 inhibition increase SERCA2 activity and Ca2 uptake in human SR fractions. A, as described under “Methods,” after
incubationof SR fractions (20g) in theabsenceorpresenceof the indicatedconcentrationsofATPandcAMPwithoutorwith cilostamide (Cil) or rolipram (Rol),
endogenous PLB, phosphorylated PLB, and-actinwere detected after SDS-PAGE and immunoblotting. Data are representative of three experiments. In these
and other Western blots PLB is predominantly monomeric, most likely due to the heating of samples before electrophoresis under reducing conditions with
Laemmli SDS sample buffer. B, bar graph summarizing pSer16PLB/PLB total ratios. Cilostamide significantly enhanced the effect of 0.1M cAMP on phosphor-
ylation of PLB. *, p  0.01 versus control (n 	 3 independent experiments). C, PDE activity in human cardiac SR fractions was assayed as described under
“Methods” and expressed as specific activity (pmol of cAMP hydrolyzed/min/mg). Results are presented as themean
 S.E. (n	 3 preparations). PDE3 activity
was determined as the cilostamide-sensitive fraction, and PDE4 activity was determined as the rolipram-sensitive fraction. PDE3 activity was significantly
higher than PDE4 activity (*, p 0.001).D, after incubation of SR fractionswithout or with the indicated concentrations of cAMP (0–10M), 45Ca2 uptakewas
measured in the presence of 0.5M free Ca2 as described under “Methods.” Results are presented as % increase due to cAMP, with basal Ca2 uptake (9.4

0.8 nmol/mg/min, n	 3) taken as 100%. cAMP significantly enhanced 45Ca2 uptake (*, p .01; **, p 0.04). E, after incubation of SR fractionswith or without
cAMP (3 M) in the presence or absence of cilostamide (1 M), 45Ca2 uptake (0.5 M free Ca2) was assayed as described under “Methods.” Results are
presented as the mean
 S.E. (n	 3). Cilostamide significantly enhanced the effect of cAMP on 45Ca2 uptake (*, p .02). F, Ca2 uptake (upper panel) and
SERCA activity (lower panel) were assayed in reaction mixtures containing Mg2 and ATP in the presence or absence of rPKAc as described under “Methods.”
Results are presented as nmol (Ca2 or Pi)/min/mg (mean
 S.E.) (n	 3). rPKAc significantly enhanced
45Ca2 uptake and SERCA2 activity (*, p .001).
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PDE3A Associates Phosphorylation-dependently with PLB,
SERCA2, andAKAP18—Weexamined the effects of phosphor-
ylation by rPKAcon the interaction of endogenous PDE3Awith
PLB, SERCA2, andAKAP18 (Figs. 4 and 5). Pooled and concen-
trated membrane LMW Superose 6 fractions (analogous to
fractions 24–34 in Fig. 3A) were divided and incubated in phos-
phorylation buffer containingATP andMgCl2 in the absence or
presence of rPKAc and then re-chromatographed on Superose
6 (S6) columns (Fig. 4) or immunoprecipitated with anti-
PDE3A-CT antibody (Fig. 5). As seen in Fig. 4, PDE3 activity in
control-pooled membrane LMW fractions exhibited an appar-
ent molecular mass of 700 kDa during re-chromatography on
S6 columns (Fig. 4, LMW Control). After incubation with
rPKAc, however, the apparent molecular mass of most of the
eluted PDE3A1 and PDE3A2 was shifted to from LMW frac-
tions to3000 kDa (Fig. 4,LMWPKA).Most of the PDE3A3,
which was not phosphorylated or only weakly phosphorylated
by rPKAc (Fig. 3), remained in the LMW peak. This indicates
that phosphorylation by rPKAc (cf. Fig. 3D) correlates with the
shift in elution of PDE3A1 and PDE3A2. As also seen in Fig. 4,
shifts from LMW to the HMW fractions were observed as well
for AKAP18, PLB, PKA-RII, and PKA catalytic subunits as well
as PP1 and caveolin 3.
As seen in Fig. 5, incubation of pooled and concentrated
membrane LMW fractions with rPKAc increased the co-im-
munoprecipitation of PDE3A with AKAP18 (not AKAP-LBC),
SERCA2, PP2A, PP1, and cav3 but reduced the co-immunopre-
cipitation of PLB. These results suggest that phosphorylation of
FIGURE 3. Analysis of PDE3A isoforms by S6 gel filtration chromatography of solubilized humanmyocardial membrane or cytosolic fractions. Upper
panels: A and B, solubilized myocardial (myc) membranes (A) and cytosolic (cyt) fractions (Fr; B) were prepared (3 mg of protein, 1 ml) and subjected to
chromatography on Superose 6 columns. Portions (10 l) of fractions (0.5 ml) were assayed for PDE3 activity (Œ) (pmol of cAMP hydrolyzed/min/0.5 ml) and
protein content (milliabsorption units (mAU)) 280 nm) (●). Molecular mass standard peaks are indicated: 1, thyroglobulin (670 kDa); 2, -globulin (158 kDa); 3,
ovalbumin (44 kDa); 4, myoglobin (17 kDa); 5, vitamin B12 (1.35 kDa). IB, immunoblot. Lower panels: A and B, portions (20 l) of the indicated fractions were
subjected to SDS/PAGEand immunoblottedwith anti-PDE3A-CT antibodies.One representative experiment is shown (n	3).C, as describedunder “Methods,”
portions of pooled HMW (H) and LMW (L) fractions (Fig. 3, A and B) from cytosol (C) and solubilizedmembrane (M) fractions were cleared by incubation with 5
gnon-immune rabbit IgGand50l of ProteinGmagnetic beads. Thebeadswere removedbyplacing the tubes in amagnetic stand, and the cleared fractions
were then incubated with 10g of non-immune IgG (IgG) or 10g of anti-PDE3A-CT (PDE3A) as indicated. Fractions were subjected to immunoprecipitation
(IP) with 50l Protein Gmagnetic beads, which were separated from the HMW and LMW fractions as described above. The beads were washed, and proteins
were eluted from the beads by boiling with Laemmli SDS sample buffer. Portions (15–20 l) of the eluted proteins were subjected to SDS/PAGE and immu-
noblotted with anti-phospho-PKA-substrate (upper panel) and anti-PDE3A-CT (lower panel) antibodies. PDE3A and pPDE3Awere detected in immunoprecipi-
tates from clearedHMWand LMW fractions incubatedwith anti-PDE3A-CT but not non-immune IgG. Bar graph, right panel, pPDE3A1/PDE3A1 (p3A1/3A1) and
pPDE3A2/PDE3A2 (p3A2/3A2) ratios in HMW and LMW peaks indicated that endogenous PDE3A1 (HMW peak) was the most highly PKA-phosphorylated
isoform and demonstrated an8-fold increase in phosphorylation of PDE3A1 and5-fold increase in phosphorylation of PDE3A2 in HMW peaks compared
with LMWpeaks (*, p 0.01). Results are representative of three individual experiments.D, as described under “Methods,” PDE3Awas immunoprecipitated by
incubation of cleared solubilized myocardial membranes with anti-PDE3A-CT and Protein G magnetic beads. The beads containing immunoprecipitated
PDE3A were separated from the solubilizedmembranes, washed, and incubated as indicated without (Ctrl) or with 250 units of rPKAc or 250 units rPKAc plus
10MPKI (PKAc inhibitor peptide) in phosphorylationbuffer containing 200MATP and5mMMgCl2 supplementedwith (upper panel) orwithout (lower panel)
[-32P]ATP. Upper panel, after incubation in phosphorylation buffer containing [-32P]ATP, the beads containing immunoprecipitated PDE3A were separated
from reactionmixtures andwashed, and 32P-labeledproteinswere eluted fromthebeadsbyboilingwith Laemmli SDS samplebuffer. Portions (15–20l) of the
eluted proteins were subjected to SDS/PAGE. -32P phosphorylation of PDE3A was detected by scanning the wet gels by phosphorimaging (GE Healthcare).
PhosphorylationwasblockedbyPKI.Middle panel, proteins onwetgelswere thenelectrophoretically transferred tonitrocellulosemembranes, andPDE3Awas
identifiedbyWestern blottingusing anti-PDE3A-CT antibody. Lower panel, PDE3 activitywas assayed in PDE3A immunoprecipitates incubatedwith orwithout
rPKAc and PKI in the absence of [-32P]ATP. Results are expressed as pmol of cAMP hydrolyzed/min. Shown are representative data from three independent
experiments. rPKAc significantly increased PDE3A activity (p 0.01); activation was blocked by PKI (PKAc inhibitor peptide).
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membrane-associated PDE3A promotes its integration into
signalosomes containing AKAP18, SERCA2, and other pro-
teins involved in the regulation of Ca2 transients andmyocar-
dial contractility by cAMP. The decreased association of PLB
with these proteins after phosphorylation by PKA is consistent
with the idea that the integration of PLB into this complex is
dependent upon its interactions with SERCA2 and AKPA18
and that these interactions are reduced by phosphorylation of
PLB by PKA at Ser-16 (2, 3, 24).
In Fig. 4, the shift of the PDE3A3 isoform from LMW to
HMWfractions after incubationwith PKA cannot be explained
by phosphorylation of PDE3A3, as it is not a substrate for PKA
(cf. Fig. 3). Although PDE3A2 can be readily phosphorylated by
rPKAc in vitro (Figs. 3D and 5) and this phosphorylation is
correlated with its shift from LMW to HMW fractions (Fig. 4),
endogenous HMWPDE3A2 is less highly phosphorylated than
PDE3A1. It is possible that PDE3A3 forms heteromeric com-
plexes with PDE3A1 and/or PDE3A2 and that phosphorylation
ofmultiple proteins contributes to the incorporation of PDE3A
isoforms into the endogenous SERCA2 regulatory signalosome.
In addition, phosphorylation at more than one site in PDE3A
isoforms may contribute to their shift in migration, as our pre-
vious work indicates that PDE3A isoforms interact directly or
indirectly with a large number of other proteins (15).
Because murine PDE3A1 is a component of a SERCA2
regulatory signalosome in murine myocardium (2, 3) and
because endogenous PDE3A1 is the most highly PKA-phos-
phorylated isoform in human myocardium (Fig. 3C), we
studied its phosphorylation-dependent interactions with
SERCA2 and AKAP18 in more detail using recombinant
forms of these proteins. The co-immunoprecipitation of
both proteins with rhPDE3A1 was increased by phosphory-
lation of rhPDE3A1 by rPKAc (Figs. 6C and 7).
To gain insight into molecular mechanisms contributing
to the phosphorylation-dependent interaction of rhPDE3A1
and rSERCA2, we generated PDE3A1 constructs with C- and
N-terminal deletions and serine-to-alanine mutations at
PKA sites in the PDE3A1 N terminus. As seen in Fig. 6C,
rSERCA2 also co-immunoprecipitated with phosphorylated
rhPDE3A-RD. rPDE3A-RD contains only the N-terminal
portion of PDE3A1 (aa 146–484), including both its unique
N-terminal extension and some of its shared sequence with
PDE3A2). SERCA2 did not co-immunoprecipitate with
rhPDE3A-510, which is a recombinant form from which
the first 510 aa of the PDE3A open reading frame were
deleted and which is not phosphorylated by rPKAc. This
indicated that interactions with rSERCA2 involved the N
terminus of rhPDE3A1.
FIGURE 4. Treatment of LMW fractions of solubilized human myocardial membranes with rPKAc induces the shift of PDE3A isoforms and
components of the SERCA2 regulatory signalosome into HMW fractions during S6 gel filtration chromatography. Solubilized myocardial mem-
branes (3 mg of protein, 1 ml) were subjected to chromatography on S6 columns as described in Fig. 3A and fractionated into LMW and HMW fractions.
As described under “Methods,” LMW fractions were pooled from two different experiments (cf. Fig. 3A) and concentrated via Centriprep YM-3. Upper
panels, pooled and concentrated Superose 6 LMW fractions were split, incubated (1 h, 30 °C) in phosphorylation buffer with 200M ATP and 5mMMgCl2
in the absence or presence of rPKAc, and re-chromatographed on Superose 6. Portions (10 l) of fractions (0.5 ml) were assayed for PDE3 activity (Œ)
(pmol of cAMP hydrolyzed/min/0.5 ml) and protein content (milliabsorption units (mAU)) 280 nm) (●). Molecular mass standards: 1, thyroglobulin (670
kDa); 2, -globulin (158 kDa); 3, ovalbumin (44 kDa); 4, myoglobin (17 kDa); 5, vitamin B12 (1.35 kDa). Bottom panels, portions (20 l) of the indicated
fractions were subjected to SDS/PAGE and immunoblotted (IB) with the indicated antibodies. Representative results from one of two independent
experiments are shown. Cav3, caveolin 3.
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With at least four PKA consensus sites (RRX(S/T)) in the
rhPDE3A1 N terminus, we inserted serine-to-alanine muta-
tions in these sites: S292A/S293A (P1), S312A (P2), S428A (P3),
S438A (P4), and S292A/S293A/S312A/S438A (P5). As seen in
Fig. 6D, P1 and P5 mutations markedly diminished PKA-stim-
ulated interactions with rSERCA2. PDE3A1 mutants P2
(S312A) and P3 (S428A) showed slightly decreased phosphory-
lation-dependent interactions with rSERCA2, whereas the
PDE3A1 P4mutation (S438A) had no effect (Fig. 6). These data
indicate that Ser-292/Ser-293 is the major PKA site regulating
the interaction of rhPDE3A1 with rSERCA2.
DISCUSSION
PDEs have critical roles in the compartmentation of cAMP
signaling (25–29). A number of studies involving many differ-
ent PDEs have demonstrated that these enzymes are recruited
to specific intracellular multiprotein complexes (signalosomes)
through protein-protein interactions and that as a result of this
localization individual PDEs are able to regulate specific cAMP-
mediated signaling pathways with great precision (25–29).
Understanding themechanisms by which PDEs are localized to
signalosomes and the consequences of this localization is espe-
cially important in cardiac muscle, where inhibitors of the
PDE3 family of enzymes are used to increase myocardial con-
tractility in patients with heart failure. In earlier work we
showed that inotropic responses to PDE3 inhibition in mice,
which correlated with increases in intracellular Ca2 tran-
sients, are attributable specifically to isoforms in the PDE3A
subfamily and that PDE3A1 is a component of a murine
SERCA2-regulatory signalosome (1–3). In the experiments
described here, we have confirmed that human PDE3A1 is part
of a similar SERCA2-, PLB- and AKAP18-containing signalo-
some localized to sarcomeric Z-bands in human cardiac myo-
cytes. We also showed that the integration of PDE3A isoforms
into this signalosome is phosphorylation-dependent and that
the interaction of PDE3A1with SERCA2 is dependent upon the
phosphorylation of PDE3A1 at Ser-292/Ser-293, a sequence in
its unique N-terminal extension.
Although both PDE3 and PDE4 have been found to co-im-
munoprecipitate with PLB in complexes from mouse and
humanmyocardium (16), our studies show that PDE3-selective
inhibition (but not PDE4 inhibition) potentiates the phosphor-
ylation of PLB by endogenous PKA and stimulation of SERCA2
activity andCa2 uptake in SR-enriched vesicles prepared from
human myocardium. This most likely reflects the higher
amount of PDE3 activity relative to PDE4 activity in SR prepa-
rations from human myocardium. Taken together, our obser-
vations provide evidence for the physiologic and therapeutic
importance of the association of PDE3Awith the SERCA2-reg-
ulatory signalosome.
As noted above, previous studies of PDE3B showed a role for
N-terminal phosphorylation in integrating adipocyte PDE3B
into signalosomes in response to insulin or 3-adrenergic
receptor agonists (5, 6, 10). N-terminal phosphorylation in
response to PKA and PKC activation has also been shown to
regulate the interactions of PDE3A isoforms with 14-3-3 and
with other (as-yet-unidentified) proteins (15). The interactions
with 14-3-3 were consequences of the phosphorylation of two
sites in the N-terminal sequence common to both PDE3A1 and
PDE3A2, Ser-312 and Ser-428; there was no evidence for the
involvement of any other phosphorylation sites in regulating
these protein-protein interactions. Our new results show that
PDE3A1 interacts directly with both SERCA2 andAKAP18 in a
phosphorylation-dependent manner. The interaction with
SERCA2 is dependent upon the phosphorylation of Ser-292/
Ser-293, a site unique to PDE3A1 that was not known to have a
role in regulating protein-protein interactions. The fact that
PDE3A2, which lacks this site, also interacts phosphorylation-
dependently with SERCA2 indicates that phosphorylation of
other sites in its sequence is responsible for this interaction
and/or that the lack of the unique N terminus in PDE3A2 alters
its phosphorylation and/or interactions with other signaling
proteins. These findings add significantly to our understanding
FIGURE5. rPKAcpromotes interactionsof PDE3Awith componentsof the
SERCA2 regulatory signalosome. Solubilizedmyocardial membranes were
prepared (3mgof protein, 1ml) and subjected to chromatography on Super-
ose 6 columns as in Fig. 3A. Membrane LMW fractions were pooled from two
different experiments (Fig. 3A) and concentrated via Centriprep YM-3.
Pooled, concentrated fractions were split into three fractions and incubated
in phosphorylation buffer with 200MATP and 5mMMgCl2 for 1 h at 30 °C in
the absence (IgG, Control) or presence (PKA-C) of rPKAc. At the completion of
these reactions, fractions were cleared with non-immune IgG and Protein G
magneticbeadsasdescribedaboveand then incubated (overnight, 4 °C)with
non-immune IgG (IgG) or anti-PDE3A-CT antibody (control, PKA-C) before
incubation and immunoprecipitation (IP) with Protein Gmagnetic beads (1 h,
4 °C). Proteins associated with the Protein G magnetic beads were eluted by
boiling in 200 l of Laemmli SDS sample buffer. Samples (15 l) were sub-
jected to SDS/PAGE and immunoblotted (IB) with specific antibodies as
shown. Input membrane proteins (10 g) were also loaded on the gels as
positive controls. Representative results from three independent experi-
ments are shown. Similar amounts of PDE3Awere immunoprecipitated in the
control fractions and in fractions incubated with rPKAc. Band intensities of
immunoprecipitated PDE3A and its interacting signaling molecules were
analyzed using an LAS3000 analyzer and presented as binding percentage
ratios of signaling molecules (rPKAc/control). For PDE3A, band intensities of
pPDEA1/pPDE3A2/pPDE3A3 in PKAc/control percentage ratios were calcu-
lated. *,p0.01 versus control (n	3 independent experiments) Cav3, caveo-
lin 3.
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of the molecular mechanisms through which PDE3A1 is local-
ized to intracellular signalosomes that control intracellular
Ca2 handling and suggest further that the interactions of each
PDE3A isoform with SERCA2 can be selectively targeted.
As noted earlier, the sequences of PDE3A1 and PDE3A2 are
identical save for the presence in the former of a unique 154-
amino acid N-terminal extension. Understanding how this
extension affects the function of PDE3A1 is, therefore, central
to understanding the unique roles of the two isoforms. A grow-
ing body of evidence indicates that several molecular mecha-
nisms are involved. The hydrophobic loops within this
sequence restrict PDE3A1 distribution to cellular and intracel-
lular membranes. Within these membranes, the protein-pro-
tein interactions of each isoform are clearly different; the 5-hy-
droxytryptamine receptor, for example, binds to PDE3A1 but
not to PDE3A2 (30). The N-terminal extension also affects the
tertiary structure of the downstream sequence; its presence
converts Ser-428 from being a strong PKC site in PDE3A2 to a
weaker one in PDE3A1. This contributes to the selective regu-
lation of these isoforms by preferential phosphorylation of
PDE3A1 at the protein binding site Ser-312 by PKA and pref-
erential phosphorylation of PDE3A2 by PKC at the protein
binding site Ser-428 (15). Because phosphorylation promotes
the association of each isoform with different proteins, this is
likely to be a factor in the two isoforms having distinct interac-
tomes. In addition, phosphorylation by PKBof the Ser-292/Ser-
293 site, which is foundwithin theN-terminal extensionunique
to PDE3A1, stimulates cAMP hydrolytic activity, providing
another mechanism by which PDE3A1 can be selectively regu-
lated (31).
FIGURE 6. rPKAc phosphorylates rhPDE3A and increases its interactions with rSERCA2. A, schemes representing protein domains and phosphorylation
sites in FLAG-tagged-PDE3A isoforms (NHR1, transmembrane domain (obligatory membrane insertion domain); NHR2, membrane association domain; CCR,
conserved C-terminal catalytic region; P1–4, predicted PKA phosphorylation sites; rhPDE3A and truncated mutants (PDE3A2, PDE3A-510, PDE3A-RD (regu-
latory domain: aa 146–484)) and protein domains in rSERCA2 (1042 amino acids, including 3–77 cation transporter N termini; 93–341, E1-E2 ATPase; 345–724,
haloacid dehydrogenase like hydrolase; 819–991, cation transporter ATPase C terminus). B, putative PKA phosphorylation sites in PDE3A designated with
asterisks. C andD, purified rSERCA2 (150 ng) (Abnova) and 50 units of FLAG-tagged rhPDE3A1 or FLAG-tagged truncatedmutants ((rhPDE3A2, rhPDE3A-510,
and rhPDE3A-RD) (C) or FLAG-taggedmutants lacking the PKA putative phosphorylation sites of rhPDE3A1 (S292A/S293A (P1), S312A (P2), S428A (P3), S438A
(P4), S292A/S293A/S312A/S438A (P5)) (D) were incubated for 30min at 30 °C inphosphorylationbuffer containing 5mMMgCl2 and200MATP in thepresence
or absence of rPKAc. As described under “Methods,” proteinswere immunoprecipitated (IP) with anti-FLAGM2magnetic beads. Immunoprecipitated proteins
bound to the anti-FLAG-M2 magnetic beads were eluted by boiling in Laemmli SDS buffer (200 l), and samples (15–20 l) of eluted proteins as well as of
reaction mixtures (lowest panel) were subjected to SDS-PAGE and Western immunoblotting (IB) as indicated with anti-SERCA2, anti-PKA substrate, and
anti-FLAG-HRP primary antibodies and anti-mouse-HRP or anti-rabbit-HRP secondary antibodies as needed. Lowest panels, input control (SERCA2). Shown are
representative blots from three independent experiments.
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Our results showing that the interaction of PDE3A1 with
SERCA2 is dependent upon the phosphorylation of Ser-292/
Ser-293 reveal a new and important mechanism whereby the
unique N-terminal extension of PDE3A1 regulates its function.
The amino acid sequence surrounding this site, aa 288–294, is
RRRRSSS, and all three serines can be phosphorylated in vitro
under different conditions (31); hence, it is likely this site can be
phosphorylated by different kinases activated in response to
different upstream signals. Phosphorylation at Ser-292/Ser-293
may promote direct interactions of PDE3A1-binding proteins
such as SERCA2 with this site. Alternatively, phosphorylation
at Ser-292/Ser-293may influence the conformation of PDE3A1
allosterically to promote binding to a different protein-protein
interface. In either case, our results suggest that an agent capa-
ble of binding to PDE3A1 in its Ser-292/Ser-293-phosphory-
lated conformation may be able to inhibit its protein-protein
interactions without affecting those of PDE3A2, thereby selec-
tively inhibiting the integration of PDE3A1 into specific
signalosomes.
Our findings add to the understanding of the mechanisms
whereby PDE3A, a component of a SERCA2-containing signa-
losome, regulates cAMP-mediated changes in contractility in
cardiac myocytes. Phosphorylation of PLB on Ser-16 causes its
dissociation from SERCA2, relieving its inhibition of SERCA2
activity and increasing Ca2 transport into the SR (24, 32, 33).
These actions increase the amplitude of intracellular Ca2
transients, which are attenuated in dilated cardiomyopathy
(34). PKA-catalyzed phosphorylation of PLB at Ser-16, induced
by isoproterenol, forskolin, or isobutylmethylxanthine, corre-
lated with increased cardiac relaxation (24, 35). The interaction
of PLB with AKAP18 is also reduced by phosphorylation of
Ser-16 (3). Phosphorylation of PDE3A1 at Ser-292/Ser-293,
which correlates with its recruitment into the SERCA2 regula-
tory signalosome,would tend to counteract this effect by reduc-
ing the concentration of cAMP in the proximity of this complex
(Fig. 8). This combination of stimulation and inhibition of
SERCA2 activity in response to PKA activation through sepa-
rate mechanisms may permit a greater degree of “fine-tuning”
of SR Ca2 handling in response to -adrenergic receptor ago-
nists. It may also explain the synergism observed when PDE3
inhibitors are used in combination with -adrenergic receptor
agonists as inotropic agents. Because PP2A and PP1 are
thought to be the principal phosphatases responsible for
dephosphorylation of PKA substrates and PLB (36), the pres-
ence of PP1 and PP2A in the complex would be expected to
catalyze the dephosphorylation of PDE3A, PLB, and other PKA
FIGURE 7. rPKAc-induced phosphorylation of rhPDE3A increases its interaction with rat rAKAP18. A, schemes representing hPDE3A1 protein
domains (NHR1, trans-membrane domain (obligatory membrane insertion domain); NHR2, membrane association domain; CCR, conserved C-terminal
catalytic region) and rAKAP18 protein domains, with RII binding site (aa 301–314) and a unique N terminus (aa 1–26). B and C, His-tagged rAKAP18
(100 ng) and 50 units of FLAG-tagged rhPDE3A1 were incubated for 30 min at 30 °C in phosphorylation buffer containing 200 M ATP and 5 mM MgCl2
in the absence or presence of the indicated concentrations (units) of rPKAc (B) or in the absence or presence of 50 units of rPKAc (C). B and C, as described
under “Methods,” proteins were immunoprecipitated (IP) with anti-His mAb magnetic beads, and immunoprecipitated proteins bound to the anti-His
mAbmagnetic beads were eluted by boiling in Laemmli SDS buffer (200 l). Samples (15–20 l) of eluted proteins as well as of reaction mixtures (Input,
lower panels) were subjected to SDS-PAGE and Western immunoblotted (IB) with anti-FLAG-HRP, anti-AKAP18-His, anti-PKAc, and anti-phospho-PKA
substrate (pPDE3A) antibodies as indicated. Similar amounts of AKAP18 were immunoprecipitated in the control groups and in reactions incubated
with rPKAc. C, as a control, rhPDE3A1 (50 units) was incubated with or without rPKAc (50 units) and with SF21 cell supernatants that contained or did not
contain rAKAP18. The bar graph summarizes binding of rhPDE3A1-FLAG with rAKAP18-His in the absence (control) and presence of rPKAc. The band
density of rhPDE3A1 was normalized to that of input rAKAP18 and calculated as the amounts of rhPDE3A1 bound to rAKAP18 in the absence (Control,
C) or presence of rPKAc; there was an9-fold increase in the association of rhPDE3A1 with AKAP18 in the presence of rPKAc (*, p 0.001). Shown are
representative blots from three independent experiments.
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substrates and return the SERCA2 complex to its basal state. Of
note, AKAP18 associates with inhibitor I and thereby can con-
trol PP1 activity (37).
Our results may have therapeutic implications. Selective
inhibition of the PDE3A isoforms associated with SERCA2
might allow the inotropic benefits of stimulating Ca2 trans-
port into the sarcoplasmic reticulum without the harmful
effects of global inhibition of PDE3 activity (2, 38). Currently
available PDE3 inhibitors, however, have little selectivity for
PDE3A versus PDE3B isoforms, whose catalytic domains are
similar, and no selectivity for individual PDE3A isoforms,
whose catalytic domains are identical (39). Blocking the inte-
gration of PDE3A1 into SERCA2 regulatory complexes either
by blocking its phosphorylation or by blocking the interactions
of phosphorylated PDE3A1 with SERCA2 may be a way of tar-
geting PDE3 activity in a specific microdomain in cardiac myo-
cytes to stimulate SR Ca2 uptake and produce inotropic
actions without the adverse consequences that accompany dif-
fuse increases in intracellular cAMP content (29, 38).
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